Vertex Pharmaceuticals VRTX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's additional paid-in capital?
- Vertex Pharmaceuticals (VRTX) reported additional paid-in capital of $4.74B in Q1 2026.
- How has Vertex Pharmaceuticals's additional paid-in capital changed year-over-year?
- Vertex Pharmaceuticals's additional paid-in capital decreased by 23.2% year-over-year, from $6.17B to $4.74B.
- What is the long-term trend for Vertex Pharmaceuticals's additional paid-in capital?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's additional paid-in capital has grown at a -8.3% compound annual growth rate (CAGR), from $7.89B to $5.12B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.